Actualités

The biotech's diversification efforts continue.

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.

Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

An ETF's label tells you the category, but the real story is always in the portfolio's actual shape.

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]

Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.

Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.

Vertex Pharmaceuticals recently announced its largest-ever acquisition.

Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...

Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology. On a conference call announcing the deal, Vertex CEO

It's been a volatile year for the company, but don't let that scare you away.

It is getting acquired by a larger firm in the sector.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.

A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.

Additional blockbuster drugs may be on the horizon.

Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the best QQQ Stocks to invest in. On July 1, Vertex Pharmaceuticals announced that the US FDA approved the expanded use of its genetic therapy, CASGEVY, to treat children as young as 2 years old. This makes it the first and only approved gene therapy for patients of this […]

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it. Vertex’s $10 Billion All-Cash Bid Fuels the Surge The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 ... Why Crinetics Stock Soared 99% This Week

CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

International Biotechnology Trust (LSE:IBT) portfolio manager Ailsa Craig joined Proactive's Stephen Gunnion to discuss the surge in biotech M&A activity, following Vertex Pharmaceuticals' acquisition of Crinetics at a 102% premium. Craig said the deal wave reflects a structural dynamic: most new drugs now originate from biotech, while large pharmaceutical companies face a significant wave of patent expiries and hold substantial cash resources. Vertex's move into rare diseases and chronic therapies makes strategic sense as it diversifies beyond its cystic fibrosis franchise — and the premium paid reflected Crinetics' strong independent position. "They would be perfectly happy to stay independent. And Vertex had to pay up if they wanted to buy them," Craig said. She outlined how IBT evaluates investments using many of the same criteria as pharma business development teams — focusing on chronic therapies, attractive valuations, strong intellectual property and companies capable of remaining independent, making them compelling acquisition targets. Around 40% of IBT's portfolio currently meets these criteria, compared with around 10% of its benchmark - a positioning Craig believes leaves the trust well placed to benefit from continued industry consolidation. Visit the Proactive YouTube channel for more interviews with leading companies and investment experts. If you enjoyed this video, please like, subscribe to the channel and enable notifications so you never miss future content. #InternationalBiotechnologyTrust #Biotech #Biotechnology #AilsaCraig #HealthcareInvesting #BiotechStocks #Pharma #Vertex #Crinetics #MergersAndAcquisitions #Investing #StockMarket #LifeSciences #PatentExpiry #HealthcareInnovation #ProactiveInvestors

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list. TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The analyst noted that […]

Vertex Pharmaceuticals stock has delivered a strong 163.3% return over the past 5 years, and the latest Discounted Cash Flow (DCF) intrinsic value estimate now points to meaningful upside relative to the current share price, even though market based valuation checks look more balanced. Over 5 years, a 163.3% total return suggests investors have already priced in a lot of success for Vertex Pharmaceuticals, which raises the bar for any further potential upside. The planned US$10b acquisition...

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.

Vertex Pharmaceuticals (VRTX) has moved into the spotlight after agreeing to acquire Crinetics Pharmaceuticals for about $10 billion in cash, a rare disease focused deal that immediately broadens its endocrinology footprint. See our latest analysis for Vertex Pharmaceuticals. Vertex Pharmaceuticals' latest share price of US$522.25 sits close to recent highs, with a 30 day share price return of 16.88% and a 1 year total shareholder return of 11.98%, adding to a 163.32% total shareholder return...